Related Experiment Video
Updated: Jul 14, 2026

Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
Published on: April 2, 2021
The use of caspofungin in HIV-infected individuals
1St Stephen's Centre, Chelsea & Westminster Hospital, London, UK. laura.waters@chelwest.nhs.uk
Abstract:
Fungal infections are a significant cause of HIV-related morbidity and mortality, particularly in the developing world, but also in countries with access to highly active antiretroviral therapy. New agents are essential to improve present efficacy rates, particularly in cases of drug resistance. Caspofungin is a new antifungal from the echinocandin class and is licensed for the treatment of candidal infections and as a second-line therapy for invasive aspergillosis. In this paper, the pharmacology, interaction and susceptibility data for this agent are reviewed and studies supporting the use of this agent in HIV-infected individuals are examined. Finally, evidence for the use of caspofungin for the treatment of Pneumocystis jiroveci pneumonia, an unlicensed indication, including a case series from our own unit is explored.
Related Concept Videos
Cryptococcal Meningitis
Antifungal Agents
Candidiasis
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Retrovirus Life Cycles
CRISPR/Cas9 Genome Editing
